Insulin Pens: Understanding Dosing Increments and Audit Risks
PAAS National® continues to see auditors flag insulin pen prescriptions for containing a dosage that does not align with the product. Most insulin pen products can be dosed in 1-unit increments; however, there are some insulin pens that range from 0.5-unit increments to 5-unit increments.
If prescriptions are written with directions that conflict with the dosing of the medication, pharmacies should clarify the directions with the prescriber and make a clinical note on the prescription. For example…
a prescription written for Toujeo® Max Solostar® with directions indicating 89 units daily must be clarified because the pen can only be dialed in 2-unit increments (i.e., the directions should either be 88 units daily of 90 units daily).
The following table outlines which insulin pens you should pay close attention to when dispensing:
Insulin | Dosing Increments |
Humalog® Junior KwikPen® | 0.5 units |
Toujeo® Max Solostar® | 2 units |
Tresiba® Flextouch® 200 units/mL | 2 units |
Humulin® R U-500 KwikPen® | 5 units |
PAAS Tips:
- Prescription directions must be clear and follow product dispensing guidelines like dosing increments
- Clarify any directions that do not follow the specific dosing intervals available for each insulin pen
- If directions must be clarified, make a clinical note on the prescription and ensure the patient label instructions are also updated
- Clinical notes should contain:
- the date you called the prescriber’s office,
- the name AND title of who you spoke with,
- a summary of what was discussed, and
- your initials
- Download the PAAS National® Insulin Medication chart which contains information on dosing increments as well as other useful information like priming units and beyond use dates, both of which can vary by product
- The PAAS Rx Days’ Supply Calculator app also contains information on dosing increments and will warn you about instructions that are not compatible with the product. Download the app for a 7-day free trial (only $5.99/year thereafter)
- Representative NDC on Electronic Prescriptions Do Not Infer Specificity - November 24, 2024
- Insulin Pens: Understanding Dosing Increments and Audit Risks - October 9, 2024
- What to Do (and Not Do) When Your Days’ Supply is Rejected - October 7, 2024